Etoposide + Cisplatin/Carboplatin

DRUG3 trials

Sponsors

Peking Union Medical College Hospital, Peking University Cancer Hospital & Institute, Tianjin Medical University Cancer Institute and Hospital

Conditions

Extensive Stage Lung Small Cell CancerLimited-stage Small Cell Lung Cancer (LS-SCLC)Neuroendocrine CarcinomaNeuroendocrine Tumors

Phase 2

Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma

Peking Union Medical College HospitalNeuroendocrine Carcinoma, Neuroendocrine Tumors

Start: 2021-10-27End: 2024-10-15Target: 28Updated: 2021-11-03

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

Not yet recruitingNCT07172412

Tianjin Medical University Cancer Institute and HospitalExtensive Stage Lung Small Cell Cancer

Start: 2025-11-30End: 2028-12-31Target: 165Updated: 2025-09-30

Unknown Phase

Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy

RecruitingNCT06869239

Peking University Cancer Hospital & InstituteLimited-stage Small Cell Lung Cancer (LS-SCLC)

Start: 2025-02-25End: 2028-01-03Target: 65Updated: 2025-03-11